Clinical Trial Detail

NCT ID NCT03024437
Title Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Roberto Pili
Indications

renal cell carcinoma

Therapies

Atezolizumab + Entinostat

Atezolizumab + Bevacizumab + Entinostat

Atezolizumab

Age Groups: adult senior

No variant requirements are available.